T he pathogenesis of ventilatorassociated pneumonia is multifactorial and has been recently reviewed (1) . The four mechanisms for bacteria to reach the lungs are aspiration (around the cuff), inhalation (through the tube), hematogenous spread, and contiguous spread. The risk of acquiring ventilator-associated pneumonia (VAP) is determined by the duration of exposure to the health care environment and the presence of host factors and treatment-related factors. Identified risk factors can either predispose to aspiration of contaminated secretions (such as witnessed aspiration, the supine position, coma, enteral nutrition, the presence of a nasogastric tube, reintubation, tracheostomy, patient transport, head trauma, and the presence of intracranial pressure monitoring) or predispose to colonization of the upper aerodigestive tract (such as prior antibiotic exposure, chronic obstructive pulmonary disease, acid-reducing stress ulcer therapy, the presence of acute respiratory distress syndrome, age Ͼ60 yrs, and severity of illness). Inhalation as a route of exposure of the lungs to bacteria can occur because of infection control lapses with contaminated nebulizers or nonsterile tracheal suctioning or manipulation of the ventilator circuit and washback of contaminated condensate. Hematogenous and contiguous routes of lung infection are rare. This article examines pulmonary aspiration in the presence of inflated cuffed tracheal tubes.
Regurgitation and pulmonary aspiration are infrequently recognized during anesthesia (2) . The exact incidence of aspiration during anesthesia is unknown, but it is clear that high-volume, lowpressure (HVLP) tracheal tube cuffs do not reliably prevent subglottic fluid from passing to the tracheobronchial tree (3) (4) (5) . Postoperative pneumonia has been linked to micro-aspiration of pathogens originating in the gastrointestinal tract (6) , and in the critically ill mechanically ventilated patient, leakage of contaminated oropharyngeal secretions occurs past tracheal tube cuffs. It is now recognized that this is a leading cause of tracheobronchial colonization and VAP (7) . The leakage occurs down longitudinal channels caused by folds in the cuff wall material (3, 5, 8) . These folds always occur in an HVLP cuff inflated within a trachea, as the diameter of the cuff must be greater than that of the trachea for the intracuff pressure to be equal to the tracheal wall pressure.
We have previously shown that the use of water-soluble lubrication on an HVLP cuff effectively dams the channels within the HVLP cuff wall and reduces the inci-dence of cuff leakage during anesthesia from 83% to 11% (p Ͻ .0001) (9) . However, this clearly only reduces pulmonary aspiration and the effect is temporary as demonstrated by the leakage of dye past lubricated tracheostomy tube cuffs after a median of 48 hrs (range 24 -120 hrs) (9) . Seegobin and Van Hasselt (3) showed that during anesthesia, an inflated lowvolume, high-pressure cuff (LVHP) prevents aspiration due to the absence of folds within the cuff walls (3). Unfortunately, tracheal wall pressure cannot be accurately and conveniently controlled with LVHP cuffs and so they carry an inherent risk of the complications of tracheal necrosis and stenosis and are unsuitable for routine use.
We have previously shown the efficacy of a silicone cuff in the prevention of aspiration in the intensive care unit. Subglottic to tracheal aspiration was reduced from 100% with a Shiley tracheostomy tube to 0% with the silicone cuff (10) . Although achieving statistical significance because of the large effect size, this study was a small pilot study (n ϭ 12), the tube was not designed for this purpose, it was labor intensive to manage, and it was not suitable for general use.
A newly developed low-volume, lowpressure (LVLP) cuff (LMA International SA, Henley, UK) is suitable for routine clinical use. It retains the advantages of protection against aspiration of the LVHP cuff but also allows the convenient and accurate maintenance of tracheal wall pressure at clinically acceptable levels (10, 11) . The LVLP tube can be used with a constant pressure inflation device that will maintain cuff inflation continuously. It is important for critical care patients that the cuff pressure is maintained at all times because this is necessary to prevent subglottic to tracheal leakage. Incorporation of integral subglottic ports on the LVLP tube allows for emptying and/or irrigation of the subglottic space to remove any pooled secretions.
This article compares the LVLP tube with a standard HVLP cuffed tracheal tube in a) a benchtop model; b) anesthetized patients; and c) critically ill patients with tracheostomies. The article also examines the effect of tracheal tube (and therefore cuff) movement on aspiration of subglottic contents to the lungs.
MATERIALS AND METHODS

Benchtop Model
Rigid Cylinder Model. A 2-cm diameter rigid cylinder (20- 4, 6, and 8 (Shiley) , and the LVLP cuffed tracheal tubes. The cuffs were inflated to 30 cm H 2 O using a cuff inflator/ pressure gauge. The Mallinckrodt (Lanz) was inflated with 25 mL of air, and the integral pressure balloons automatically corrected tracheal wall pressure. The Bivona Fome Cuff self-inflates due to the expansion of the material within the HVLP cuff. The LVLP cuff was inflated to 80 cm H 2 O to achieve a calculated tracheal wall pressure of 30 cm H 2 O (Appendix). Dye was placed above the cuffs and photographed to demonstrate the mechanism of leakage ( Fig. 1) .
Static Pig Trachea Model. Nine-centimeter lengths of five pig tracheas slaughtered within the previous 24 hrs were chosen for size to span the range for the adult human trachea diameter. The range for human tracheal diameter calculated from a postmortem study (12) was 1.4 -2.6 cm. The tracheas were suspended at 45°to the vertical to simulate semirecumbency and then sequentially intubated in random order by one of the investigators so that the cuff center was 4 cm below the upper tracheal edge. All the HVLP cuffs from the rigid model (discussed previously) were tested. The HVLP cuff pressures were maintained at 30 cm H 2 O (22 mm Hg) with a constant pressure inflation device (Tracoe, Neu-Isenburg, Germany), and the LVLP cuff was maintained at 80 cm H 2 O, that is, 30 cm H 2 O above the plateau pressure producing a calculated tracheal wall pressure of 30 cm H 2 O (22 mm Hg) (4, 10, 11) (Appendix). The cuff inflator had been checked against a mercury column to confirm accuracy. The tube type was hidden so that the observer was blinded to the tube type used. Three and a half milliliters of blue dyed water was placed above the cuff and a stopwatch begun.
Static Test. The blinded observer noted if dye was observed to drip past the cuff. After 15 mins if no dye had leaked, then this was recorded as no leak.
Movement Test. A standard movement was then applied to the proximal tube to simulate the inevitable movements that can occur in the critically ill during routine clinical care (e.g., during patient positioning or with accidental traction on the tube). The observer again noted if dye was observed to drip past the cuff. After 15 mins if no dye had leaked, then this was recorded as no leak. Each cuff was tested in each trachea three times. Anesthetic Technique. All patients received a standard anesthetic technique. The patients were not premedicated, and an intravenous catheter was placed in a forearm or hand vein for drug and fluid administration. Induction of general anesthesia was performed with fentanyl (2 g/kg), propofol (3-4 mg/kg), and mivacurium (0.1 mg/kg) to facilitate tracheal intubation with a size 8 internal diameter LVLP or Sheridan cuffed tracheal tube. The low dose of mivacurium was chosen to facilitate tracheal intubation, yet because of the rapid metabolism of the drug, a spontaneously breathing technique could be established soon after the start of surgery. The return of neuromuscular function was monitored by clinical variables such as tidal volume. Anesthesia was maintained using sevoflurane (1-3%). Perioperative analgesia was not standardized, and no patients received nasogastric tubes. Neither tube had lubricating gel applied to the cuff. Following intubation of the trachea, the cuff was inflated with air to achieve a tracheal wall pressure of 30 cm H 2 O (22 mm Hg) and maintained at this with a constant pressure inflation device. The devices used were the Tracoe (Neu-Isenburg, Germany) cuff inflator for the HVLP cuff and a specially designed cuff inflator (constant pressure inflation device) for the LVLP cuff (LMA International SA, Henley, UK) shown in the Appendix. Half a milliliter of blue food dye (E122) was diluted to 3.6 mL with normal saline and instilled into the subglottic space slowly over a 2-min period to prevent the generation of an abnormally high subglottic pressure.
Clinical Studies
Static Test. Following surgery, anesthesia was continued with the patient in a 30°head up position breathing spontaneously. Five minutes later tracheal suctioning was performed using a 14-CH catheter and a Clement's adaptor capable of generating a maximum pressure of Ϫ400 mm Hg. It was impossible for the investigator conducting the anesthesia to be blinded to tube type as the two tubes are different in appearance. To reduce possible bias, the tracheal suction catheter was shown (against a white background) to an independent observer who was unaware of the tracheal tube type used. If the observer noted blue dye in the catheter, then the cuff was deemed to have leaked.
Movement Test. If leakage did not occur, then a standardized movement was applied to the proximal tracheal tube (axial rotation of 90°left and right and proximal to distal movement through 5-7 cm). This was done to simulate the inevitable tracheal tube movement that occurs in the critically ill. The test was then repeated. The subglottis and oropharynx were then emptied, by applying suction with a syringe on the subglottic ports, before extubation in the lateral reverse Trendelenburg position.
Critically Ill Patients With Tracheostomies. This is a prospective open observational study involving patients with tracheostomy tubes, recovering from respiratory failure, who have weaned from mechanical ventilation and are able to attempt the restitution of oral intake (a swallow assessment). Data were collected for sequential critically ill patients with either a Portex Soft Seal or LVLP cuffed tracheostomy tube. The tracheal wall pressure was maintained at 30 cm H 2 O (22 mm Hg) for both cuffs using constant pressure inflation devices. The devices used were the same as for the anesthesia study above, that is, the Tracoe cuff inflator for the HVLP cuff and a specially designed cuff inflator (constant pressure inflation device, see Appendix) for the LVLP cuff as shown in the Appendix. The HVLP cuffs were inflated to 30 cm H 2 O and the LVLP cuff was maintained at 80 cm H 2 O, with a calculated tracheal wall pressure ϭ 30 cm H 2 O (22 mm Hg) (Appendix). At 10 and 60 mins following a swallow of 30 mL of blue-dyed fluid (E122), a tracheal aspirate was performed and the secretions were inspected for dye; if present, the assessment was failed. If dye was not present in the trachea, then a subglottic aspirate was inspected to determine whether laryngeal penetration without pulmonary aspiration had occurred.
Statistical Analysis
Seegobin and Van Hasselt (3) demonstrated a 100% leakage rate with an HVLP cuff. Studies using the Portex Profile cuff have demonstrated 87% and 83% aspiration rates (4, 9) . However, in an unpublished pilot study examining the Portex Soft-Seal cuff in anesthetized patients, we found an incidence of aspiration of only 23%. This difference was possibly due to the improvement in elasticity of the cuff and the thinner cuff material of the Soft Seal (13, 14) , but differences might also be due to nonstandardization of cuff movements during the studies. The Sheridan CF cuff material is much thinner than the Portex Profile cuff, and so we estimated that the aspiration rate with this cuff might be Ն20%. Based on the previous studies, we estimated that the incidence of aspiration in the LVLP group would be 0%. With an alpha value of .05 and a beta value of .2, 38 patients would be required.
We analyzed 2 ϫ 2 contingency tables using Fisher's exact test. Means and ranges are shown where appropriate.
RESULTS
Rigid Tracheal Model
In the rigid cylinder, all the HVLP cuffs permitted leakage but the LVLP cuff did not ( Fig. 1 ) (0% vs. 100%, n ϭ 10, p Ͻ .01). The leakage rate for the Shiley cuffs was very rapid because of the thick cuff wall and hence wide channels. The leakage rate for the Mallincrodt Hi-Lo was much slower because of the narrower channels within the wall. Leakage with the Mallincrodt Hi-Lo was facilitated by cuff movement (rotational and longitudinal). The LVLP cuff did not leak even with movement.
Pig Trachea Study
The five tracheas had mean diameters of 1.84 cm (range 1.5-2.45 cm).
Static Study. Leakage in the static study occurred on 60 of 135 of occasions for the HVLP cuffs (44%). The LVLP cuff prevented leakage in all the tracheas tested (0 of 15) ( Table 1) .
Tube Movement Study. Movement of the cuff promoted leakage in the HVLP group increasing the leakage rate to 107 of 135 occasions (79%). Movement did not cause leakage in the LVLP group (0 of 15) ( Table 2 ).
Anesthetized Patient Study
Static Test. Before manipulation of the tube, 0% of the LVLP cuffs leaked and 22% of the Sheridan CF HVLP cuffs leaked (p ϭ .052) ( Table 3) .
Tube Manipulation Test. Following manipulation of the tube, 5% of the LVLP cuffs leaked and 67% of the Sheridan CF HVLP cuffs leaked (p ϭ .001) ( 
Critically Ill Patients With Tracheostomies
Sixty-seven assessments were performed in 16 patients (Table 4 ). In the HVLP group, 49% of all assessments were failed (seven of ten patients having failed on one or more occasions). In the LVLP group, 0% of assessments failed (none of six patients failed at any assessment; p ϭ .01). Sixteen (57%) of the passed assessments in the LVLP demonstrated laryngeal penetration without pulmonary aspiration (subglottic dye detected). Figure 2 is a graphic summary of the five studies.
DISCUSSION
The LVLP cuff reduced pulmonary aspiration in the pig trachea benchtop model and in anesthetized and critically ill patients. This is because the LVLP cuff does not have the channels permitting fluid leakage that are found within the walls of HVLP cuffs.
There are four mechanisms for the pathogenesis of VAP: aspiration (around the cuff), inhalation (through the tube), hematogenous spread, and contiguous spread; however, aspiration of secretions from the colonized upper aerodigestive tract (the stomach, pharynx, sinuses, and dentition) is the leading cause of VAP (or perhaps more correctly called tracheal tube associated pneumonia) (7, 15, 16) . Indeed, measures to decrease oropharyngeal aspiration and decontamination of these secretions appear to be effective in Table 2 .
ID, inner diameter; LVLP, low volume, low pressure. reducing VAP and improving survival (17, 18) . The mechanism for tracheal soiling may be due to both intermittent loss of cuff pressure and aspiration past the appropriately inflated tracheal tube cuff along the folds within the cuff wall (3-5, 7). The folds within a HVLP cuff may not always allow leakage as demonstrated in the current anesthesia study. This may be because of an exact fit within the trachea (the resting tracheal diameter closely matching the resting natural diameter of the cuff) and aspiration rate may also depend on the viscosity of the secretions, positive end-expiratory pressure, intermittent positive-pressure ventilation, and patient position (8) . Theoretically, warming HVLP cuffs to room temperature could reduce or eliminate the channels; however, this did not happen over a 2-to 5-day period in patients with a Portex Profile tube in place (4). We have previously demonstrated that the channels within a cuff wall may temporarily block if a water-soluble gel is applied to the cuff before intubation (9). This effect is not absolute, is not prolonged in the critically ill, and cannot be relied on. Notably, the effect of tube movement dramatically increased the aspiration rate in the HVLP anesthesia group (from 22% to 67%). This may explain why aspiration is much more common in the critically ill patient than during routine general anesthesia when patient movement relative to the tube may be minimized. The LVLP cuff prevented aspiration continuously even during tube movement. The single failure of the LVLP cuff in the anesthesia study was possibly related to an accidental temporary endobronchial intubation but could have been caused by a transient and undetected cuff pressure loss or else a true failure of the cuff to prevent leakage. In the anesthesia study, the securing flange was not used and we believe that this could help to prevent both unplanned extubation and accidental intermittent endobronchial intubation in the critically ill patient. Notably, in the critical care study when a securing flange was used (with the tracheostomy tube), aspiration was prevented completely and over a much longer period of time. The incidence of unplanned extubation in the intensive care unit may be as common as 8%, increasing both length of stay and risk of VAP (19) . Within this study there were no incidences of aspiration in the critical care group, but a limitation of the study was that the LVLP cuff was not formally tested for a prolonged period. It is our experience when using this cuff clinically for prolonged ventilation that aspiration can occur if the tracheal is accidentally decannulated, if there is endobronchial intubation, or if cuff pressure is unintentionally lost. Cuff pressure loss is avoided with prolonged intubation by using the constant pressure controller and ensuring tight connections with the avoidance of three-way taps in the connector tubing. An important feature of the cuff pressure controller is that if the power supply is interrupted, then the cuff does not deflate yet the users are alerted. Cuff deflation has occurred with a disconnection of the constant pressure controller tubing from the box, although this does not cause a significant aspiration if the subglottic space has been regularly emptied and/or cleaned. To date, 28 days is the longest period that a patient has been ventilated and this was without demonstrable aspiration. In previous studies (with early prototypes of the LVLP cuff), aspiration of dye has been prevented in critical care with both the LVLP and the HVLP cuff maintained in constant inflation for up to 7 days (4, 10).
Tracheal wall damage is a complication of prolonged tracheal intubation and cuff inflation. A limitation of study design was that bronchoscopy and radiologic imaging were not included in the protocol for reasons of patient acceptance and cost. However, all surviving study pa- tients receiving either an LVLP or HVLP cuff were clinically reviewed following hospital discharge, and no respiratory symptoms suspicious of tracheal stenosis were found. A further limitation to the study design was that because of the dissimilar appearance of the tubes, blinding was difficult. In the anesthesia study, to reduce this bias, the tracheal suction catheter was assessed for the presence of dye by an independent observer who was unaware of the tube type used.
The incidence of VAP in the critically ill is 10 -25%, increasing length of stay, costs, and mortality by 5-27% (20) . Recent studies also show an increase in costs associated with the acquisition of a VAP. Drs. Shorr and Wunderink in their editorial in Critical Care Medicine went as far as stating that "even marginally beneficial preventive interventions are likely to yield significant net savings" and limit mortality (21) .
The time has come to consider the replacement of the standard tracheal tube with a tube designed to minimize the multiple risk factors that cause VAP.
The design of a tracheal tube could address five important risk factors:
1. Reducing cuff leakage 2. Maintaining cuff pressure (relative risk of VAP if failure to maintain Ͼ20 cm H 2 O ϭ 4.23) (14) 3. Minimizing subglottic secretions with aspiration of the subglottic space (approximately 50% reduction in VAP) (21) (22) (23) (24) (25) 4. Preventing tube movement and accidental extubation (relative risk of VAP ϭ 5.3) (18) 5. Minimizing biofilm formation and tube occlusion (absolute risk unidentified)
The prevention of cuff leakage is achieved by an appropriately placed LVLP cuff as demonstrated in this study.
Rello et al. (15) found that a persistent intracuff pressure Ͻ20 cm H 2 O in patients not receiving antibiotics was independently associated with the development of pneumonia. Logic dictates that to reduce the aspiration of secretions, the LVLP cuff should be maintained inflated at all times. Cuff pressure maintenance has not been compared with intermittent measurement and reinflation in a controlled trial for possible risk reduction of VAP. It is known, however, that cuff pressure monitoring practices are variable and monitoring is often not routinely performed in critical care practice (22) (23) (24) .
Cuff pressure estimation techniques alone are poor, with over-and underestimation occurring in a third of patients (25) .
The use of subglottic secretion drainage has been shown in five studies to reduce VAP (three achieving statistical significance) (26 -30) . The Mallinckrodt Hi-Lo Evac tube, however, is not ideal as the port tends to occlude by sucking in the tracheal mucosa, causing failure in some patients some of the time, and severe tracheal lesions occur in sheep exposed to continuous suctioning of the subglottic space (31, 32) . Intermittent suctioning may be safer as the tracheal mucosa will only temporarily be exposed to a negative pressure. Intermittent suctioning makes little sense with a cuff that may continuously leak and will at best only reduce the volume of secretion aspiration. It does, however, make sense to use this technique with the LVLP cuff as aspiration is prevented between episodes of subglottic drainage. Irrigation of the subglottic space is also possible with the LVLP cuff if care is taken not to apply an irrigation pressure of greater than the tracheal wall pressure (30 cm H 2 O, or 22 mm Hg).
Tracheal tube biofilm formation in the distal third of the tracheal tube inner lumen is time dependent and represents a permanent source of infectious material that may contaminate the lower respiratory tract and narrow the lumen causing tube occlusion (33) (34) (35) (36) (37) . The luminal surface of the LVLP tracheal tube is coated with medical grade nonstick coating that minimizes the adhesion of biological material.
Multiple risk factors are addressed by the design of the LVLP tracheal tube. It may be expected that the benefits of each risk factor reduction would be at least in part additive. The high cost of VAP means that even a marginal benefit would translate to a large cost reduction (21) , and this would justify the increased costs of the LVLP tracheal tube. For example, assume that the incidence of VAP in a general intensive care unit is 20% and the attributable mortality rate is 25%, with the excess costs of acquiring a VAP being $10,000. If all patients were to receive an improved tracheal tube costing $100, then to remain cost neutral the incidence would only have to be reduced by 1-19%. Further evaluation of the LVLP tracheal tube should examine the benefits of what is effectively a "care bundle" facilitated by the tube-that is, the prevention of aspiration, maintenance of cuff pressure, clearance of subglottic secretion, reduction of potential biofilm, and reduction of unplanned extubation. The important outcome measures will be reduction in length of stay, reduction in unplanned extubation, reduction in aspiration, and reduction in mortality and a cost analysis rather than the imprecise outcome of VAP reduction. Outcomes related to the separate components of the "care bundle" should also be examined. For example, is aspiration prevention achieved reliably with the cuff/constant pressure controller without the controlled environment of a clinical study? There is a potential additive effect of intermittent subglottic secretion drainage, and as is our current practice, the use of intermittent subglottic irrigation as an aid to oral and upper airway hygiene. It remains unknown whether biofilm reduction will occur with the nonstick coating applied to the inner aspect of the tube, and future studies could also examine biofilm formation and tube occlusion in tubes with and without this coating. The potential reduction in accidental extubation with the securing flange system that is an integral part of the tube could also be examined.
In summary, we have shown in a rigid tracheal model a reduction in the incidence of leakage from 100% in the HVLP group to 0% in the LVLP group. In the pig tracheal model, there was a reduction in the incidence of leakage from 44% (before tube movement) and 79% (after tube movement) in the HVLP group to 0% in the LVLP group. In anesthetized patients, there was a reduction in the incidence of leakage from 22% (before tube movement) and 67% (after tube movement) in the HVLP group to 5% in the LVLP group. In critically ill patients, there was a reduction in the incidence of leakage from 49% in the HVLP group to 0% in the LVLP group. 
CONCLUSIONS
Pulmonary aspiration can be prevented by the LVLP cuff if it is continuously and correctly inflated in the trachea of the intubated patient. In contrast, pulmonary aspiration commonly occurs in the critically ill patient with a correctly inflated HVLP cuff in place, and this causes VAP and increases morbidity and mortality. The likely higher cost of the LVLP tube might indicate its selection for use in those patients at high risk of VAP such as the critically ill and high-risk emergency and elective surgical patients.
APPENDIX
The tracheal and tracheostomy tube have been designed to address some of the multiple risk factors that are associated with pulmonary aspiration and/or the development of ventilator-associated pneumonia in the critically ill.
LVLP Tracheal Tube
The tracheal tube is made of silicone and is wire reinforced (Fig. 3) . The tube is flexible with no preformed curve and is supplied with a bougie to facilitate both intubation during direct laryngoscopy and tube exchange. The following features are present.
Cuff. The cuff is designed to prevent aspiration associated with HVLP cuffs, which is a key step in the pathogenesis of ventilator-associated pneumonia (Fig. 3) . The LVLP cuff offers advantages over an LVHP cuff as an LVLP cuff allows for accurate tracheal wall pressure control whereas an LVHP cuff does not and is associated with tracheal injury. The LVLP cuff is made of silicone of high compliance, and the principles of its function have been described previously (10, 11) . The inflation characteristics of the cuff are such that over the adult tracheal diameter range, the pressure within the cuff remains nearly constant (plateaus) at 33-37 mm Hg (45-50 cm H 2 O). When the cuff pressure is increased beyond this plateau, then the tracheal wall pressure rises linearly. After tracheal intubation, the cuff is kept at an intracuff pressure of 55-58 mm Hg and this produces a consistent tracheal wall pressure of 18 -22 mm Hg (25- 30 cm H 2 O) . This is because only a fixed proportion of the intracuff pressure is transmitted to the tracheal mucosa. Thus, the tracheal wall pressure can be conveniently maintained at an acceptable pressure (i.e., below mucosal perfusion pressure) in all adult tracheas at a single intracuff pressure (55-58 mm Hg or 75-80 cm H 2 O).
Constant Pressure Inflation Device. Silicone tends to slowly leak air over time, and so for prolonged use a constant pressure inflation device is used to ensure uninterrupted cuff inflation and airway protection (Fig. 4) . It is vitally important that secretions above the cuff that have been prevented from soiling the tracheobronchial tree by the LVLP cuff are not intermittently allowed to pour past the cuff during accidental cuff deflations. A constant pressure cuff inflation device has been designed to keep the cuff pressure uninterrupted and at a safe level. The constant pressure inflation device is calibrated to indicate to the clinician the tracheal wall pressure. This is not equal to the intracuff pressure because the cuff does not even touch the tracheal wall (tracheal wall pressure ϭ 0) until Ն33 mm Hg of cuff pressure is achieved. Thereafter, the tracheal wall pressure rises in proportion to the intracuff pressure (10, 11) . The calculated tracheal wall pressure defaults at 20 mm Hg; this is achieved by raising the intracuff pressure to 50 mm Hg (Fig. 3) .
Subglottic Ports. A separate external subglottic port was used in the anesthesia study to standardize the dye instillation in both the LVLP and HVLP groups (Fig. 3) . The tube has triple subglottic ports to enable the intermittent removal of secretions that collect over time in the subglottic space above the cuff.
Nonstick Inner Lumen Coating. The inner surface of the tube is coated with Parylene, a nonstick biocompatible coating that facilitates the passing of tracheal suction catheters and inhibits the attachment of biological material to the inner lumen.
Adjustable Flange. The tracheal tube has an adjustable flange and protective sleeve/bite block (Fig. 3) . This facilitates fixation of the tube and is designed to reduce tube movement and unplanned extubation. The protective sleeve lies adjacent to the teeth and is designed to function as a bite block. The adjustable flange was not used in the anesthesia study because it inhib- ited access into the oral cavity for the dental surgeon, and notably without the flange there was one probable episode of tube migration into the right main bronchus.
Tracheostomy Tube
The tracheostomy tube is made of silicone and is wire reinforced. It is 15 cm long and has an adjustable flange. The tube is flexible and so is supplied with a malleable wire introducer.
Cuff: designed to prevent aspiration; identical on the trachea and tracheostomy tube Cuff pressure inflation device: ensures uninterrupted cuff inflation Subglottic ports: enable the intermittent removal of secretions that collect over time in the subglottic space above the cuff Nonstick inner lumen coating: Parylene, a nonstick biocompatible coating Adjustable flange
